These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 12889482)

  • 1. Nucleoside-free regimen tested.
    AIDS Patient Care STDS; 2003 Jun; 17(6):309-10. PubMed ID: 12889482
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-HIV agents. Efavirenz versus indinavir: who really wins?
    TreatmentUpdate; 2000 Feb; 12(1):4-5. PubMed ID: 12125628
    [No Abstract]   [Full Text] [Related]  

  • 3. Treating advanced HIV infection.
    Boffito M; Bonora S; Sinicco A; Raiteri R; Milia MG; Khoo SH; Hoggard PG; Back DJ; Di Perri G
    J Acquir Immune Defic Syndr; 2003 Nov; 34(3):344-5. PubMed ID: 14600582
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
    Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using ritonavir with indinavir in cases of virologic failure.
    TreatmentUpdate; 2001; 12(12):7. PubMed ID: 11570095
    [No Abstract]   [Full Text] [Related]  

  • 6. DMP 266 and indinavir combination.
    AIDS Patient Care STDS; 1997 Aug; 11(4):287-8. PubMed ID: 11361845
    [No Abstract]   [Full Text] [Related]  

  • 7. Efavirenz in HIV infection.
    Casado JL; Moreno S
    N Engl J Med; 2000 Apr; 342(17):1290-1. PubMed ID: 10787332
    [No Abstract]   [Full Text] [Related]  

  • 8. Maintenance of successful ritonavir-boosted indinavir and efavirenz therapy in an HIV-infected patient with tuberculosis.
    Boyd MA; Burger DM; Phanuphak P; Cooper DA
    AIDS; 2006 Apr; 20(7):1083-5. PubMed ID: 16603870
    [No Abstract]   [Full Text] [Related]  

  • 9. [5 years' data are convincing. Lopinavir as primary therapy is effective and safe in the long term].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():92. PubMed ID: 15373069
    [No Abstract]   [Full Text] [Related]  

  • 10. Switching from protease inhibitors to the non-nuke efavirenz.
    TreatmentUpdate; 2001; 12(12):3. PubMed ID: 11570089
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir-ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors.
    Panagopoulos P; Tsiodras S; Antoniadou A; Katsarolis I; Papadopoulos A; Poulakou G; Giamarellou H
    Clin Microbiol Infect; 2006 May; 12(5):486-9. PubMed ID: 16643529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
    Staszewski S; Morales-Ramirez J; Tashima KT; Rachlis A; Skiest D; Stanford J; Stryker R; Johnson P; Labriola DF; Farina D; Manion DJ; Ruiz NM
    N Engl J Med; 1999 Dec; 341(25):1865-73. PubMed ID: 10601505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009.
    Boyd MA; Siangphoe U; Ruxrungtham K; Duncombe CJ; Stek M; Lange JM; Cooper DA; Phanuphak P
    HIV Med; 2005 Nov; 6(6):410-20. PubMed ID: 16268823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term immunologic response in HIV-infected patients with CD4 cell counts Le Moing V; Eid Z; Ecobichon JL; Duval X; Longuet P; Elbim C; Brun-Vezinet F; Leport C; Vilde JL
    Ann Med Interne (Paris); 2001 Feb; 152(1):11-4. PubMed ID: 11240420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy.
    Badía X; Podzamczer D; Moral I; Roset M; Arnaiz JA; Loncà M; Casiró A; Rosón B; Gatell JM;
    Antivir Ther; 2004 Dec; 9(6):979-85. PubMed ID: 15651756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy.
    Jubault V; Burgard M; Le Corfec E; Costagliola D; Rouzioux C; Viard JP
    AIDS; 1998 Dec; 12(17):2358-9. PubMed ID: 9863885
    [No Abstract]   [Full Text] [Related]  

  • 17. Update on antivirals.
    Proj Inf Perspect; 1997 Nov; (23):8-11. PubMed ID: 11365381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DMP 266 on the horizon.
    Vazquez E
    Posit Aware; 1997; 8(5):25. PubMed ID: 11364636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Saquinavir plus ritonavir reduce viral load by 99.9 percent.
    Vazquez E
    Posit Aware; 1996; 7(6):8-9. PubMed ID: 11363983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily.
    Konopnicki D; De Wit S; Poll B; Crommentuyn K; Huitema A; Clumeck N
    HIV Med; 2005 Jan; 6(1):1-6. PubMed ID: 15670245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.